Deoxyshikonin reversibly inhibits cytochrome P450 2B6

Biopharm Drug Dispos. 2020 Apr;41(4-5):221-225. doi: 10.1002/bdd.2230. Epub 2020 May 22.

Abstract

Deoxyshikonin, a natural shikonin derivative, is the major component of Lithospermum erythrorhizon and exhibits various pharmacological effects such as lymphangiogenetic, antibacterial, wound healing, and anticancer effects. To investigate the herb-drug interaction potential associated with deoxyshikonin, the inhibitory effects of deoxyshikonin on eight major cytochrome P450 (CYP) enzymes were examined using cocktail substrate-incubated human liver microsomes. Deoxyshikonin strongly inhibited CYP2B6-catalyzed bupropion hydroxylation, with a Ki value of 3.5 μM, and the inhibition was confirmed using purified human CYP2B6. The inhibition was reversible because the inhibitory effect of deoxyshikonin was not dependent on the preincubation time. The results indicated that deoxyshikonin-induced drug-drug interaction should be considered when any herb containing deoxyshikonin is used for conventional medications.

Keywords: cytochrome P450 2B6; deoxyshikonin; herb-drug interaction; reversible inhibition.

MeSH terms

  • Cytochrome P-450 CYP2B6 Inhibitors / pharmacology*
  • Cytochrome P-450 Enzyme System / metabolism*
  • Herb-Drug Interactions*
  • Humans
  • Microsomes, Liver / metabolism
  • Naphthoquinones / pharmacology*

Substances

  • Cytochrome P-450 CYP2B6 Inhibitors
  • Naphthoquinones
  • deoxyshikonin
  • Cytochrome P-450 Enzyme System